RenovoRx, Inc. (RNXT) NASDAQ
0.91
-0.0102(-1.11%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
0.91
-0.0102(-1.11%)
Currency In USD
| Previous Close | 0.92 |
| Open | 0.95 |
| Day High | 0.97 |
| Day Low | 0.91 |
| 52-Week High | 1.45 |
| 52-Week Low | 0.7 |
| Volume | 237,436 |
| Average Volume | 375,161 |
| Market Cap | 33.89M |
| PE | -2.76 |
| EPS | -0.33 |
| Moving Average 50 Days | 0.94 |
| Moving Average 200 Days | 0.99 |
| Change | -0.01 |
RenovoRx Advancing RenovoCath® Adoption at U.S. Cancer Centers, Strengthening Clinical and Commercial Momentum
GlobeNewswire Inc.
Feb 27, 2026 1:30 PM GMT
Over the past year, RenovoRx has Tripled Commercially Active U.S. Cancer Centers and Centers Requesting Access to RenovoCath, its FDA-Cleared Device Over 700 RenovoCath Procedures Successfully Completed Since FDA Clearance in 2014 Company Appoints Ra
RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Radiology Annual Scientific Meeting
GlobeNewswire Inc.
Feb 26, 2026 1:30 PM GMT
Accepted Abstract Highlights Metabolic Response Observations Following Chemotherapeutic Drug-Delivery via the TAMP™ Therapy Platform in Patients Diagnosed with Locally Advanced Pancreatic CancerMOUNTAIN VIEW, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE)
RenovoRx Establishes RenovoCath® Medical Advisory Board
GlobeNewswire Inc.
Feb 10, 2026 1:30 PM GMT
Advisory Board Members Will Provide Strategic Clinical Insights to Further Advance the TAMP™ Therapy Platform in Clinical Indications of High Unmet Medical NeedMOUNTAIN VIEW, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or t